Overview

Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).
Phase:
Phase 1
Details
Lead Sponsor:
Handok Inc.
Handok Pharmaceuticals Co., Ltd.
Treatments:
Apaziquone